Skip to main content

Testing for Diabetic Retinopathy with AI in More Settings

Provider in Home with Senior Patients Medical Team Looking at Xray

Increasingly, more patients are having their eyes examined for diabetic retinopathy (DR) using artificial intelligence (AI), specifically IDx-DR, a new Federal Drug Administration (FDA)-approved technology. The system does not need a doctor to interpret the results. Essentially, patients can be tested in non-eye care settings, such as primary care offices. Approximately, 24,000 people lose vision each year from DR. If detected in its earliest stages, vision loss and blindness are almost entirely preventable. Read more at this Cision PR Newswire article.